LoadingLoadingLoadingNet buying: insiders sold $0 and bought $162K on the open market in 90 days (SEC Form 4). Congress: net selling of $186K to $514K in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full results8 funds hold a position and insiders have been net buying.
Buys/Adds (3)
Two Sigma
$129.9M
added
Citadel
$89.1M
added
Millennium
$69.1M
added
Buys (2)
Mcevoy Ashley
$162K
bought
Stonesifer Timothy C.
$400K
bought
Sells (1)
Borio Luciana
$60K
sold
Top-trader positions in PODD could not be loaded.
Hyperliquid positioning - not every stock is covered
Last report
Aug 5, 2026
Period ending
Jun 30, 2026
Earnings per share
$1.44 expected
Revenue
Financial statements: Alpha Vantage
Estimates as of Oct 24, 2026
EPS expected
$1.50 to $1.66
Revenue expected
23 analysts
Last 30 days
Split both ways
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 5, 2026 | $1.66 / $1.44Alpha Vantage | +15.28% beat | $801.7M No estimate | Unavailable |
| Mar 31, 2026 | May 6, 2026 | $1.42 / $1.19Alpha Vantage | +19.33% beat | $761.7M No estimate | Unavailable |
| Dec 31, 2025 | Feb 18, 2026 | $1.55 / $1.48Alpha Vantage | +4.73% beat | $783.8M No estimate | Unavailable |
| Sep 30, 2025 | Nov 6, 2025 | $1.24 / $1.15Alpha Vantage | +7.83% beat | $706.3M No estimate | Unavailable |
| Jun 30, 2025 | Aug 7, 2025 | $1.17 / $0.93Alpha Vantage | +25.81% beat | $649.1M No estimate | Unavailable |
| Mar 31, 2025 | May 8, 2025 | $1.02 / $0.79Alpha Vantage | +29.11% beat | $569.0M No estimate | Unavailable |
| Dec 31, 2024 | Feb 20, 2025 | $1.15 / $1.02Alpha Vantage | +12.63% beat | $597.5M No estimate | Unavailable |
| Sep 30, 2024 | Nov 7, 2024 | $0.90 / $0.76Alpha Vantage | +18.42% beat | $543.9M No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $706.3M | $783.8M | $761.7M | $801.7M |
| Cost of what it sold | $196.2M | $215.2M | $232.6M | $239.1M |
| Gross profit | $510.1M | $568.6M | $529.1M | $562.6M |
| What it spent | ||||
| Research and development | $77.2M | $90.9M | $89.7M | $88.1M |
| Sales and admin | $315.2M | $331.4M | $317.2M | $344.8M |
| Total operating expenses | $392.4M | $422.3M | $406.9M | $432.9M |
| What was left | ||||
| Operating profit | $117.7M | $146.3M | $122.1M | $129.7M |
| Interest on debt | $15.6M | $19.6M | $14.7M | $13.5M |
| Profit before tax | $122.8M | $140.2M | $113.0M | $118.7M |
| Tax | $35.2M | $38.5M | $21.9M | $23.7M |
| Net profit | $87.6M | $101.6M | $91.1M | $95.0M |
| EBITDA | $160.4M | $184.2M | $153.9M | $158.9M |
This stock is trending upward, and looks overbought after a fast run-up.
Trend
Constructive
60 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Insulet Corp (GOV.DU) stock major holders
Leans bearishOct 21Piper Sandler sets USD 160.00 target for iRhythm stock
NeutralOct 20Insulet stock stands 13.26 percent above its 52-week low
Leans bullishOct 20DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study
Leans bullishOct 20DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study
Leans bullishOct 202 Profitable Stocks to Keep an Eye On and 1 We Question
Leans bullishOct 19Press Release Distribution & Media Outreach Platform for PR Agencies
BearishOct 192 Profitable Stocks to Keep an Eye On and 1 We Question
BullishOct 1922 macro signals shaping PODD right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results